mardi 12 septembre 2017

Onco Actu du 12 septembre 2017

2.6 Etiologie - Environnement

Purdue researchers create device to identify risks for breast cancer [Purdue University]

2.9 Etiologie - Tabac

‘Epigenetic’ Changes From Cigarette Smoke May be First Step in Lung Cancer Development [Johns Hopkins]

3.1 Prévention - Tabac

Using history as a guide to end tobacco addiction [Stanford Medicine]

3.7 Prévention - Alcool

Drinks industry accused of downplaying 'alcohol-cancer risk' [NHS Choices]

3.8 Prévention - Alimentation

Wholegrains and bowel cancer – what you need to know [Cancer Research UK]

4.12 Biopsies liquides

British biotech behind blood tests for cancer strikes deal with German drugs giant [The Telegraph]

4.2 Dép., diag. & prono. - Génome

Too few women with breast cancer get genetic testing [Reuters]

4.9 Dép., diag. & prono. - Sein

Hologic's 3Dimensions™ Mammography System Now Available in Europe [PR Newswire]

5. Traitements

A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It [Forbes]

5.12 Immunothérapies

Viruses may boost immunotherapy success [Cancer Research UK]

5.12.1 Immunothérapies - partenariats

Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC) [Transgene]

5.12.2 Immunothérapies - CAR-T

Amid Setback, Researchers Forge Ahead with “Off-the-Shelf” Immune Cells to Treat Cancer [MIT Technology Review]

5.12.5 Immunothérapies - Pharma

AstraZeneca Wins in Cancer by Going Its Own Way [Bloomberg]

5.12.6 Immunothérapies - AMM

CAR T-Cell Therapy Approved for Some Children and Young Adults with Leukemia [NCI]

5.12.8 Immunothérapies - Economie

New Gene-Therapy Treatments Will Carry Whopping Price Tags [NY Times]

5.2 Pharma

Pharma’s five favorite tricks to protect a monopoly [STAT]

5.2.3 Pharma - économie

Roche shares hit by trial flops, fears over biosimilar defense [Reuters]

Lilly Cuts Back, Again [In the Pipeline]

5.3 Traitements - FDA, EMA, NICE...

How the EU regulates medicines [EMA]

5.4 Traitements - Economie

Gottlieb Targets Drug Development Costs, Clinical Development Efficiencies [RAPS]

R&D Costs For Cancer Drugs Are Likely Much Less Than Industry Claims, Study Finds [NPR]

Dr. Gottlieb's speech to the Regulatory Affairs Professsionals Society (RAPS) 2017 Regulatory Conference [FDA]

What Does It Cost to Create a Cancer Drug? Less Than You’d Think [NY Times]

5.6 ESMO

#ESMO17 roundup: Idera shares spike on early TLR9 combo data; Erytech touts pancreatic cancer PhIIb data [EndPoints]

ESMO need-to-know: Imfinzi wows, Incyte unveils, plus Lilly, Merck, BMS and more [FiercePharma]

5.6.11 ESMO- Rein

ESMO 2017: Rocapuldencel-T Shows Potential Benefit in Metastatic Renal Cell Carcinoma [ESMO]

5.6.14 ESMO - Ovaire

TESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual Meeting [Tesaro]

5.6.15 ESMO - VADS

ESMO 2017: Durvalumab Shows Promising Clinical Benefit in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [ESMO]

ESMO 2017: Nivolumab Demonstrates Antitumour Activity Post-progression in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [ESMO]

ESMO 2017: Single Agent Atezolizumab in Head and Neck Cancer [ESMO]

ESMO 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer [ESMO]

5.6.16 ESMO - Appareil digestif

ESMO: Merck's Keytruda-chemo combo spurs big response in new stomach cancer patients across the PD-L1 board [FiercePharma]

5.6.4 ESMO - Poumon

Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer [Pfizer]

5.6.5 ESMO - Mélanome & Peau

Idera Pharmaceuticals Presents Positive Phase 1 Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy [Idera]

ESMO 2017: BRIM8 Data Shows Benefit with Adjuvant Vemurafenib in Resected BRAFV600 Positive Melanoma [ESMO]

ESMO 2017: Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma [ESMO]

ESMO 2017: Adjuvant Dabrafenib Plus Trametinib Significantly Lowers Risk of Death in Stage III BRAF V600–Mutated Melanoma [ESMO]

Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma [Novartis]

5.6.7 ESMO - Immunothérapies

Cancer immunotherapy proves itself in earlier-stage disease [Reuters]

6. Lutte contre les cancers

Two U.S. scientists awarded Balzan Prize for cancer research [STAT]

6.1 Observation

Call for action as UK 'falls behind rest of Europe for life expectancy growth' [The Guardian]

6.11 Patients

New Guideline Aims to Improve Clinician Communication With Patients [ASCO]

6.6 Publications

We have the technology to save peer review – now it is up to our communities to implement it [LSE Impact Blog]

Bias, Conflicts, Spin: The 8th Olympiad of Research on Science & Publishing Begins [Absolutely Maybe]

6.7 DMP, Big Data & applis

Merck to co-lead Big Data alliance [PharmaTimes]

IBM Watson versus cancer: Hype meets reality [Science-Based Medicine]

6.9 Controverses

Carlo Croce, Ohio State researcher facing misconduct allegations, suing New York Times for defamation [Retraction Watch]